Novel Approaches to Machine Learning and Artificial Intelligence in Cancer Research and Care

Guest Editors:

Dr. Caroline Chung
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Dr. Christopher Gibbons
1. Division of Internal Medicine, Section of Patient Centered Analytics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2. MD Anderson Center for INSPiRED Cancer Care (Integrated Systems for Patient-Reported Data), The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Deadline for manuscript submissions:
30 September 2024

Message from the Guest Editors

This Special Issue of *Cancers* will highlight cutting-edge research addressing new strategies to improve the performance and safe clinical translation of machine learning (ML) and artificial intelligence (AI) approaches to oncology research and care. Topics of interest in data may include new standards for data quality and provenance, and opportunities around the inclusion of metadata in model development and implementation; Topics of interest in models may include efficient and interpretable algorithms suitable for deployment in health systems; systems for deploying and monitoring algorithms to enable accelerated safe deployment across health systems. Regarding model evaluation, we welcome papers presenting new strategies for evaluating ML and AI through clinical trials or ensures the validity of text-generation tools. From a systems perspective, systems for deploying and monitoring algorithms in practice as well as approaches and standards for flagging model behaviors that may lead to unexpected outcomes are of interest.

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us